Skip to main content

Table 2 Key dates and relevant protection periods for sofosbuvir, imatinib, and trastuzumab, based on SPCs granted in France [56, 64, 71]

From: Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib

Product

Sofosbuvir

Imatinib

Trastuzumab

Year of market launch

2013

2001

1999

Year sales revenue surpassed R&D investment

2015

2003

2000

Basic patent expiry date

26/03/2028

25/03/2013

15/06/2012

SPC term

> 9 months

> 3 years 8 months

> 2 years 1 month

SPC expiry date

17/01/2029

21/12/2016

29/07/2014